zuclopenthixol acetate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	4075	85721-05-7

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

zuclopenthixol acetate
clopixol acuphase

Molecular weight: 443
Formula: C24H27ClN2O2S
CLOGP: 5.03
LIPINSKI: 1
HAC: 4
HDO: 0
TPSA: 32.78
ALOGS: -5.90
ROTB: 7

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2B,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,JAK3,MAP3K21,MAP3K7,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MET,MTOR,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKDC,SIK2,SIK3,STK33,TEK,TTK	46
kinase-selectivity-class	AXL,BRAF,EPHB4,MAPK7,PDK4,SIK2,STK33,TTK	8
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Blood prolactin abnormal	1049.40	171.91	163	2582	3103	90622599
Anosognosia	1037.11	171.91	163	2582	3359	90622343
Disturbance in social behaviour	1008.90	171.91	163	2582	4025	90621677
Sexual dysfunction	986.55	171.91	163	2582	4641	90621061
Metabolic disorder	914.67	171.91	163	2582	7307	90618395
Personality change	858.26	171.91	154	2591	7167	90618535
Dystonia	782.64	171.91	163	2582	16656	90609046
Dyskinesia	666.88	171.91	165	2580	36369	90589333
Sedation	645.61	171.91	170	2575	48001	90577701
Suicide attempt	539.76	171.91	163	2582	75236	90550466
Blood glucose increased	502.24	171.91	163	2582	95083	90530619
Insurance issue	191.51	171.91	48	2697	10910	90614792

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anosognosia	298.74	49.96	51	2166	993	42618125
Blood prolactin abnormal	298.20	49.96	51	2166	1004	42618114
Disturbance in social behaviour	264.60	49.96	50	2167	1753	42617365
Metabolic disorder	221.25	49.96	51	2166	4737	42614381
Sexual dysfunction	208.66	49.96	52	2165	6723	42612395
Dystonia	189.16	49.96	55	2162	12735	42606383
Dyskinesia	178.80	49.96	62	2155	25328	42593790
Personality change	161.64	49.96	41	2176	5678	42613440
Sedation	114.36	49.96	47	2170	30428	42588690
Suicide attempt	98.71	49.96	48	2169	46052	42573066
Blood glucose increased	95.93	49.96	55	2162	73644	42545474
Extrapyramidal disorder	67.27	49.96	27	2190	16385	42602733
Psychotic disorder	64.20	49.96	31	2186	29177	42589941
Neuroleptic malignant syndrome	63.49	49.96	28	2189	21444	42597674
Anxiolytic therapy	61.87	49.96	9	2208	57	42619061
Drug therapy enhancement	60.72	49.96	9	2208	66	42619052
Iatrogenic injury	60.49	49.96	13	2204	869	42618249
Antipsychotic drug level increased	55.54	49.96	17	2200	4649	42614469
Antipsychotic drug level decreased	51.27	49.96	12	2205	1181	42617937

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Blood prolactin abnormal	1121.18	63.87	184	4319	3651	110581145
Anosognosia	1110.07	63.87	184	4319	3890	110580906
Disturbance in social behaviour	1070.30	63.87	184	4319	4874	110579922
Sexual dysfunction	980.59	63.87	185	4318	8345	110576451
Metabolic disorder	935.94	63.87	184	4319	10326	110574470
Personality change	879.25	63.87	176	4327	10826	110573970
Dystonia	786.91	63.87	187	4316	25618	110559178
Dyskinesia	704.50	63.87	197	4306	51249	110533547
Sedation	636.87	63.87	195	4308	69488	110515308
Suicide attempt	545.77	63.87	191	4312	103203	110481593
Blood glucose increased	485.15	63.87	187	4316	132309	110452487
Insurance issue	202.64	63.87	53	4450	10559	110574237
Adverse drug reaction	185.81	63.87	89	4414	105470	110479326
Drug ineffective	126.31	63.87	222	4281	1520318	109064478
Personality change due to a general medical condition	112.49	63.87	18	4485	297	110584499
Condition aggravated	87.58	63.87	127	4376	734709	109850087
Extrapyramidal disorder	75.01	63.87	32	4471	28835	110555961
Anxiolytic therapy	64.06	63.87	9	4494	57	110584739
Drug therapy enhancement	64.06	63.87	9	4494	57	110584739

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D014149	Tranquilizing Agents
MeSH PA	D014150	Antipsychotic Agents
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018492	Dopamine Antagonists
CHEBI has role	CHEBI:37890	α-adrenergic antagonist
CHEBI has role	CHEBI:37955	H<small><sub>1</sub></small>-receptor antagonist
CHEBI has role	CHEBI:48279	serotonergic antagonist
CHEBI has role	CHEBI:48561	dopaminergic antagonist
CHEBI has role	CHEBI:65190	first generation antipsychotic

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.47	Basic
pKa2	3.47	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
C0149491	UMLSCUI
C060342	MESH_SUPPLEMENTAL_RECORD_UI
349S2ZHF05	UNII
6436640	PUBCHEM_CID
58338	RXNORM
004070	NDDF
387566002	SNOMEDCT_US
395931006	SNOMEDCT_US
427940003	SNOMEDCT_US
C0009026	UMLSCUI
CHEBI:135722	CHEBI
DB13841	DRUGBANK_ID
12454	PUBCHEM_CID
1315	INN_ID
D003006	MESH_DESCRIPTOR_UI
349S2ZHF05	INXIGHT DRUGS

Pharmaceutical products:

None